KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash & Equivalents (2016 - 2025)

Pfizer (PFE) has disclosed Cash & Equivalents for 17 consecutive years, with $1.1 billion as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 9.49% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, up 9.49% year-over-year, with the annual reading at $1.1 billion for FY2025, 9.49% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $1.1 billion at Pfizer, down from $1.3 billion in the prior quarter.
  • The five-year high for Cash & Equivalents was $3.1 billion in Q4 2023, with the low at $416.0 million in Q4 2022.
  • Average Cash & Equivalents over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 78.6% in 2022, then surged 585.82% in 2023.
  • Over 5 years, Cash & Equivalents stood at $1.9 billion in 2021, then tumbled by 78.6% to $416.0 million in 2022, then soared by 585.82% to $2.9 billion in 2023, then crashed by 63.44% to $1.0 billion in 2024, then increased by 9.49% to $1.1 billion in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $1.1 billion, $1.3 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.